An EXSCEL post hoc simulation and mediation analysis showing conventional risk-factor changes explain only a modest share of once-weekly exenatide’s cardiovascular effects. PICO summary and expert commentary.
Browsing: Diabetes
Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
A manufacturer-sponsored secondary analysis found a digital diabetes logbook nearly doubled the odds of reaching HbA1c 6.5% or below at 3 months, with associated real-world glucose reductions. PICO summary and expert commentary.
A small single-blind RCT found that a family-centered empowerment program raised illness acceptance and self-management scores at six weeks in adults with type 2 diabetes. PICO summary and expert commentary.
A one-year randomised controlled trial testing whether pharmacist-led collaborative care improves EQ-5D quality of life and HbA1c versus routine care in adults with diabetes. PICO summary and expert commentary.
A Phase 1 crossover study in healthy Korean volunteers found the enavogliflozin/gemigliptin fixed-dose combination pharmacokinetically equivalent to the separate tablets, with food not altering enavogliflozin exposure. PICO summary and expert commentary.
A 52-week open-label randomized trial found once-weekly semaglutide reduced LDL cholesterol and shifted lipoprotein subfractions toward a less atherogenic profile versus sitagliptin in obese type 2 diabetes. PICO summary and expert commentary.
A secondary analysis of a 6-month randomized trial found that higher baseline weight-loss self-efficacy predicted at least 5% weight loss in both diet arms, with BMI and age as arm-specific predictors. PICO summary and expert commentary.
A 12-week randomised trial in older adults with type 2 diabetes testing whether combined aerobic plus resistance exercise improves sleep and abdominal fat. PICO summary and expert commentary.
A 453-patient non-inferiority trial found once-daily prolonged-release pregabalin worked about as well as immediate-release pregabalin for diabetic peripheral neuropathy, with both beating placebo. PICO summary and expert commentary.
A three-arm RCT shows 24 g/day dietary fibre improves HbA1c and the FIB-4 fibrosis marker in type 2 diabetes with MASLD. PICO summary and expert commentary for clinicians.